Table 2 Assessment of methodological quality including proportion of secondary breast cancer patients included, quality rating, GRADE rating and overall study weighting (n = 19)
No | Author (year) | Sample size (% of SBC patients) included | Quality ratinga | GRADE ratingb | Overall study weightingc |
|---|---|---|---|---|---|
1 | Accordino et al. (2017) [26] | 4251/4521 (100) | Moderate | Moderate | 1 |
2 | Alves et al. (2022) [33] | 296/2525 (12%) | Low | Low | 3 |
3 | Cole et al. (2019) [34] | 65,380/601,680 (11) | Moderate | Moderate | 2 |
4 | Falchook et al. (2017) [35] | 5855/28,731 (20) | Moderate | Moderate | 2 |
5 | Ferreira et al. (2020) [36] | 10,816/151,931 (7) | Low | Low | 3 |
6 | Giap et al. (2023) [27] | 60,685/60,685 (100) | Moderate | Moderate | 2 |
7 | Ozmen et al. (2015) [37] | 29/1031 (3) | Low | Low | 3 |
8 | Recondo et al. (2019) [38] | 268/13 (5) | Low–moderate | Low–moderate | 3 |
9 | Sathe et al. (2023) [28] | 6082/6082 (100) | Moderate | Moderate | 1 |
10 | Shih et al. (2009) [39] | 42,804/207,581 (21) | Moderate | Moderate | 2 |
11 | Shiovitz et al. (2015) [40] | 3583/76,259 (5) | Moderate | Moderate | 2 |
12 | Skinner et al. (2021) [32] | 608/608 (100) | Moderate | Moderate | 2 |
13 | Small et al. (2012) [41] | 57,148/773,233 (7) | Moderate | Moderate | 1 |
14 | Statler et al. (2019) [30] | 6234/6234 (100) | Moderate | Moderate | 1 |
15 | Vas Luiz et al. (2015) [31] | 4364/4364 (100) | Moderate | Moderate | 2 |
16 | Vyas et al. (2021) [5] | 1089/1089 (100) | Moderate | Moderate | 1 |
17 | Wan & Jubelirer (2015) [35] | 4533/4533 (100) | Moderate | Moderate | 1 |
18 | Wang & Du (2015) [42] | 1100/25,128 (4) | Low–moderate | Low–moderate | 3 |
19 | Wolfson et al. (2015) [43] | 1441/75,987 (4) | Low–moderate | Low–moderate | 3 |